Syfovre
Active Ingredient(s): PegcetacoplanFDA Approved: * February 17, 2023
Pharm Company: * APELLIS PHARMS
Category: Genetic Disorders
Pegcetacoplan, sold under the brand name Empaveli among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH).[2][3][4][5] The most common side effects include injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, and fatigue.[2][4] Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, a... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
Syfovre 15 mg/.1ml Intravitreal Injection, Solution
NDC: 73606-020
Labeler:
Apellis Pharmaceuticals, Inc.